A Phase 3 interventional study of Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg) and Placebo to match aficamten in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Cytokinetics. Completed at 71 sites in 13 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Cytokinetics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic — 2 open to participants now, 5 under way, 4 of them phase 3. aficamten · Cardiomyopathy, Hypertrophic.
Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, this one is the 4th largest by enrollment, is one of 3 that started in 2023, is one of 5 in phase 3, and was the 6th registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →2 of the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic are open now, in 12 countries. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 18–90
Cytokinetics · Sites in United States, Argentina, Australia and 16 more countries
Ages 18–85
By country, each count listing its studies:
aficamten: first FDA approval 2025 (MYQORZO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 7 · Phase 4 1
First in 2018; this study’s year is marked. 3 started in 2023.
This study's enrollment of 175 is above the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 96 across the 11 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 4 most frequent:
Cytokinetics is the lead sponsor of 41 studies on the registry; 3 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.
Cytokinetics has 7 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
1 of the studies testing aficamten in Cardiomyopathy, Hypertrophic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07600177Oregon Health and Science UniversityMavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who meet all the following criteria at screening may be included in the trial:
Diagnosed with oHCM per the following criteria by cardiac magnetic resonance imaging (CMR) or echocardiography -
Has an end-diastolic LV wall thickness as measured by the echocardiography core laboratory:
Has a screening echocardiogram with the following determined by the echocardiography core laboratory:
Exclusion Criteria:
Any of the following criteria will exclude potential participants from the trial:
Significant valvular heart disease
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive doses of 5 mg, 10 mg, 15 mg or 20 mg of aficamten (CK-3773274) plus placebo for metoprolol succinate with dose levels guided by echocardiography assessments for up to 24 weeks.
Drug: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg) · Drug: Placebo to match metoprolol succinate
Patients will receive 50 mg, 100 mg, 150 mg or 200 mg of metoprolol succinate plus placebo for aficamten (CK-3773274) with dose levels guided by echocardiography and heart rate assessments for up to 24 weeks.
Drug: Placebo to match aficamten · Drug: Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)
Drug page: Aficamten
Aficamten (CK-3773274) tablets administered orally
Placebo for aficamten (CK-3773274) administered orally
Drug page: Metoprolol
Metoprolol succinate tablets administered orally
Placebo for metoprolol succinate administered orally
Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)
Effect of aficamten compared with metoprolol succinate on exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Exercise capacity was determined through changes in peak oxygen uptake (pVO2) after 24 weeks of treatment. pVO2 was measured by cardiopulmonary exercise testing (CPET) on a treadmill or bicycle. A higher pVO2 indicates better cardiorespiratory fitness.
Time frame: Baseline to Week 24
Proportion of Patients With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class
Effect of aficamten compared with metoprolol succinate on NYHA Functional Classification
Time frame: Baseline to Week 24
Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)
Effect of aficamten compared with metoprolol succinate on participant health status was measured by change in KCCQ-CSS. The KCCQ is a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, quality of life, and social limitation of patients with heart failure symptoms. The CSS is the sum of the physical limitation score and the total symptom score. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms.
Time frame: Baseline to Week 24
Change in Left Ventricular Mass Index (LVMI)
Effect of aficamten on mass of the heart as compared with metoprolol succinate
Time frame: Baseline to Week 24
Change in Left Atrial Volume Index (LAVI)
Effect of aficamten on size of the heart as compared with metoprolol succinate
Time frame: Baseline to Week 24
Change From Baseline Values in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)
Effect of aficamten on NT-proBNP as compared with metoprolol succinate. For change in NT-proBNP from baseline to Week 24, the log transformed proportional change up to Week 24 was analyzed using a mixed model for repeated measures (MMRM) then the estimate was back transformed to obtain the ratio.
Time frame: Baseline to Week 24
Change in Post-Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G)
Effect of aficamten on post-Valsalva LVOT-G as compared with metoprolol succinate
Time frame: Baseline to Week 24
| Milestone | Aficamten | Metoprolol |
|---|---|---|
| Started | 88 | 87 |
| Completed treatment | 87 | 84 |
| Completed | 87 | 86 |
| Not completed | 1 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 |
Effect of aficamten compared with metoprolol succinate on exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Exercise capacity was determined through changes in peak oxygen uptake (pVO2) after 24 weeks of treatment. pVO2 was measured by cardiopulmonary exercise testing (CPET) on a treadmill or bicycle. A higher pVO2 indicates better cardiorespiratory fitness.
| mL/kg/min | Aficamten | Metoprolol |
|---|---|---|
| Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) | 1.07 ± 2.767 | -1.24 ± 2.186 |
Effect of aficamten compared with metoprolol succinate on NYHA Functional Classification
| Participants | Aficamten | Metoprolol |
|---|---|---|
| Proportion of Patients With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class | 45 | 23 |
Effect of aficamten compared with metoprolol succinate on participant health status was measured by change in KCCQ-CSS. The KCCQ is a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, quality of life, and social limitation of patients with heart failure symptoms. The CSS is the sum of the physical limitation score and the total symptom score. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms.
| points on a scale | Aficamten | Metoprolol |
|---|---|---|
| Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) | 15.3 ± 1.56 | 8.3 ± 1.57 |
Effect of aficamten on mass of the heart as compared with metoprolol succinate
| g/m^2 | Aficamten | Metoprolol |
|---|---|---|
| Change in Left Ventricular Mass Index (LVMI) | -9.19 ± 2.492 | -4.34 ± 2.486 |
Effect of aficamten on size of the heart as compared with metoprolol succinate
| mL/m^2 | Aficamten | Metoprolol |
|---|---|---|
| Change in Left Atrial Volume Index (LAVI) | -3.87 ± 0.785 | 3.12 ± 0.789 |
Effect of aficamten on NT-proBNP as compared with metoprolol succinate. For change in NT-proBNP from baseline to Week 24, the log transformed proportional change up to Week 24 was analyzed using a mixed model for repeated measures (MMRM) then the estimate was back transformed to obtain the ratio.
| ratio | Aficamten | Metoprolol |
|---|---|---|
| Change From Baseline Values in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) | 0.26 (0.23 to 0.31) | 1.38 (1.18 to 1.61) |
Effect of aficamten on post-Valsalva LVOT-G as compared with metoprolol succinate
| mmHg | Aficamten | Metoprolol |
|---|---|---|
| Change in Post-Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G) | -40.34 ± 3.098 | -5.44 ± 3.100 |
Collected over 28 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aficamten | 1/88 (1.1%) | 7/88 (8%) | 46/88 (52.3%) |
| Metoprolol | 0/87 (0%) | 6/87 (6.9%) | 43/87 (49.4%) |
| Event | Aficamten | Metoprolol |
|---|---|---|
| Atrial fibrillationCardiac disorders | 2/88 | 1/87 |
| Acute left ventricular failureCardiac disorders | 0/88 | 1/87 |
| Blood loss anaemiaBlood and lymphatic system disorders | 1/88 | 1/87 |
| Abdominal wall hematomaGastrointestinal disorders | 0/88 | 1/87 |
| Non-cardiac chest painGeneral disorders | 0/88 | 1/87 |
| Ischemic strokeNervous system disorders | 0/88 | 1/87 |
| SyncopeNervous system disorders | 0/88 | 1/87 |
| HematomaVascular disorders | 0/88 | 1/87 |
| HypertensionVascular disorders | 0/88 | 1/87 |
| HypotensionVascular disorders | 0/88 | 1/87 |
| Event | Aficamten | Metoprolol |
|---|---|---|
| DizzinessNervous system disorders | 6/88 | 15/87 |
| Upper respiratory tract infectionInfections and infestations | 12/88 | 10/87 |
| FatigueGeneral disorders | 5/88 | 9/87 |
| HypertensionVascular disorders | 9/88 | 2/87 |
| PalpitationsCardiac disorders | 3/88 | 8/87 |
| Angina pectorisCardiac disorders | 8/88 | 4/87 |
| COVID-19Infections and infestations | 7/88 | 4/87 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/88 | 6/87 |
| HeadacheNervous system disorders | 6/88 | 6/87 |
| NasopharyngitisInfections and infestations | 1/88 | 6/87 |
| Age, Continuous(Years) | Aficamten | Metoprolol | Total |
|---|---|---|---|
| Mean | 58.9 ± 13.33 | 56.5 ± 13.06 | 57.7 ± 13.21 |
| Sex: Female, Male(Participants) | Aficamten | Metoprolol | Total |
|---|---|---|---|
| Female | 36 | 37 | 73 |
| Male | 52 | 50 | 102 |
| Ethnicity (NIH/OMB)(Participants) | Aficamten | Metoprolol | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 11 | 22 |
| Not Hispanic or Latino | 73 | 73 | 146 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Race/Ethnicity, Customized(Participants) | Aficamten | Metoprolol | Total |
|---|---|---|---|
| Race — White | 70 | 70 | 140 |
| Race — Black or African American | 1 | 0 | 1 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Race — American Indian or Alaska Native | 0 | 0 | 0 |
| Race — Other | 1 | 1 | 2 |
| Race — Not Reported | 1 | 4 | 5 |
| Race — Unknown | 2 | 0 | 2 |
| Race — Asian | 13 | 12 | 25 |
| Region of Enrollment(Participants) | Aficamten | Metoprolol | Total |
|---|---|---|---|
| Brazil | 0 | 1 | 1 |
| Canada | 2 | 0 | 2 |
| China | 11 | 11 | 22 |
| Denmark | 4 | 1 | 5 |
| France | 2 | 2 | 4 |
| Germany | 1 | 0 | 1 |
| Hungary | 5 | 6 | 11 |
| Israel | 0 | 3 | 3 |
| Italy | 4 | 0 | 4 |
| Netherlands | 1 | 3 | 4 |
| Spain | 12 | 16 | 28 |
| United Kingdom | 3 | 5 | 8 |
| United States | 43 | 39 | 82 |
| Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)(mL/kg/min) | Aficamten | Metoprolol | Total |
|---|---|---|---|
| Mean | 19.52 ± 4.786 | 20.19 ± 5.313 | 19.86 ± 5.052 |
| Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)(Points on a Scale) | Aficamten | Metoprolol | Total |
|---|---|---|---|
| Mean | 65.5 ± 17.01 | 66.0 ± 5.99 | 65.8 ± 16.47 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2023 to primary completion in Feb 2025, 20 months.
Results were first posted in Jun 2026, 1 year 3 months after primary completion.
Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 20 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aficamten
Cardiomyopathy, Hypertrophic →